Business
Ocumetics Announces Commencement of Biocompatibility and Animal Studies for Updated Lens Design
(TheNewswire) Calgary, Alberta – TheNewswire - June 20 , 2023 - ...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Announces Commencement of Biocompatibility and Animal Studies for Updated Lens Design\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta\n \n \n –\n \n \n TheNewswire -\n \n \n June 20\n \n \n , 2023 -\n \n \n Ocumetics Technology Corp.\n \n \n (TSXV:OTC)\n(OTC:OTCFF) (FRA:2QBO) (“\n \n \n Ocumetics\n \n \n ” or the “\n \n \n Company\n \n \n ”)\n \n \n is pleased to announce that the Company has reached a\nmajor milestone with the start of biocompatibility and animal studies\nfor its updated lens design.\n \n \n \n \n As a result of extensive product testing and\npreliminary animal studies over the past 18 months, the Ocumetics\nresearch and development team made several design enhancements to the\nOcumetics accommodating lens. On April 19, 2023, the Company announced\nproduct design lockdown.\n \n \n \n \n “Our latest lens design update addressed an\nimplantation challenge identified from our first animal study and\nfeedback received from our Medical Advisory Board at the 2023 ASCRS\nmeeting,” said Dean Burns, Ocumetics’ President and CEO.\n \n \n \n \n “These new studies are to ensure that the lens design\nhas a safe biological response when implanted within the eye and it is\na significant milestone towards meeting FDA regulatory safety\nrequirements\n \n \n ,” said Dr. Barbara Fant,\nPresident of Clinical Research Consultants, Ocumetics’ regulatory\nconsultant.\n \n \n \n \n “It is exciting to see the technology we have\ndeveloped coming to fruition,” added Ocumetics’ Chief Medical\nOfficer, Dr. Doyle Stulting.\n \n \n \n \n The biocompatibility studies will take 4-5 months to\ncomplete.  Ocumetics expects to begin planning its first-in-human\nproof of concept studies by Q4 2023.\n \n \n \n \n About Ocumetics\n \n \n \n \n Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)\n(FRA: 2QBO) is a Canadian research and development company that\nspecializes in adaptive intraocular lens designs. Ocumetics is in the\npreclinical study stage of a game-changing technology for the\nophthalmic industry.  Ocumetics has developed an expandable\nintraocular lens that fits within the capsular bag following\nextracapsular cataract extraction.  It is des...